A comparison of repeated low-level red light and low-dose atropine for myopia control: A two-year retrospective study
Purpose: To compare the long-term efficacy between repeated low-level red light (RLRL) therapy and low-dose atropine (LDA) eye drops for myopia control. Methods: Treatment naïve myopic children receiving RLRL or LDA therapy were retrospectively included. The spherical equivalent (SE) and axial lengt...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-10-01
|
| Series: | Photodiagnosis and Photodynamic Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1572100025002868 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Purpose: To compare the long-term efficacy between repeated low-level red light (RLRL) therapy and low-dose atropine (LDA) eye drops for myopia control. Methods: Treatment naïve myopic children receiving RLRL or LDA therapy were retrospectively included. The spherical equivalent (SE) and axial length (AL) were evaluated at baseline and 6-, 12-, and 24-month follow-up. The myopia progression and regression were compared between groups. Results: In total, 122 myopic children were enrolled. The SE progression and AL elongation were significantly less in the RLRL than in the LDA group at 6 months (P = 0.002, SE; P = 0.004, AL), 12 months (P < 0.001) and 24 months (P < 0.001). For patients with RLRL, the SE progression was greater during the second than the first year (P = 0.05). The proportion of patients with SE regression in the RLRL group was greater than that in the LDA group at 12 months (P = 0.003), and the AL shortening proportion was significantly greater in the RLRL group than in the LDA group at 6 months (P = 0.001), 12 months (P = 0.001), and 24 months (P = 0.049). Eight adverse events were reported in the RLRL group without irreversible structural damage. Conclusion: The present research demonstrates that RLRL treatment is more effective than 0.01 % atropine in delaying myopia progression and observes a greater percentage of patients with SE regression and AL shortening in myopic children over two years. |
|---|---|
| ISSN: | 1572-1000 |